Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Receivables (2022 - 2025)

Historic Receivables for Spero Therapeutics (SPRO) over the last 4 years, with Q3 2025 value amounting to $2.5 million.

  • Spero Therapeutics' Receivables fell 9538.49% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year decrease of 9538.49%. This contributed to the annual value of $52.5 million for FY2024, which is 350.91% up from last year.
  • Per Spero Therapeutics' latest filing, its Receivables stood at $2.5 million for Q3 2025, which was down 9538.49% from $26.9 million recorded in Q2 2025.
  • In the past 5 years, Spero Therapeutics' Receivables ranged from a high of $55.5 million in Q2 2024 and a low of $1.1 million during Q4 2022
  • Over the past 4 years, Spero Therapeutics' median Receivables value was $50.7 million (recorded in 2023), while the average stood at $35.7 million.
  • Its Receivables has fluctuated over the past 5 years, first skyrocketed by 457684.5% in 2023, then plummeted by 9538.49% in 2025.
  • Quarter analysis of 4 years shows Spero Therapeutics' Receivables stood at $1.1 million in 2022, then soared by 4576.85% to $50.7 million in 2023, then increased by 3.51% to $52.5 million in 2024, then crashed by 95.31% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $26.9 million for Q2 2025, and $24.3 million during Q1 2025.